Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David H. Mack
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 54
- Beta
- 1.37
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -4.83
Financials
Net Income
$-18.09MEBITDA
$-18.89MFree Cash Flow
$-14.58MEPS (diluted)
$-0.34Shares Outstanding (diluted)
53.39M+1665.4%Operating Expenses
$18.88MCash & Debt
$79.43MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-77.74M | $-1.48 |
| 2024 | $0.00 | $-58.71M | $-1.14 |
| 2023 | $0.00 | $-68.96M | $-1.44 |
| 2022 | $0.00 | $-73.32M | $-1.61 |
| 2021 | $0.00 | $-57.85M | $-1.28 |
| 2020 | $0.00 | $-34.44M | $-2.40 |
| 2019 | $0.00 | $-25.35M | $-0.59 |
| 2018 | $0.00 | $-17.54M | $-5.80 |
Valuation
PMVPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (6)
- Newszacks.com·19d ago·Positive
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? PMV Pharmaceuticals, Inc. (PMVP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PMVP's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
…cribed $50 Million Public Offering of Securities PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate…
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
…Announces Proposed Public Offering of Securities PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock, to certain investor…
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
… Cancer Data From PYNNACLE Phase 2 Pivotal Trial PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multicenter, single-arm, registrational Phase 2 trial is assessing rezatapopt as monotherapy …
View source ↗ - Newszacks.com·47d ago·Positive
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock? PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.31 per share
Typical surprise +8.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.34 vs $-0.39beat
- Tue, May 12$-0.34 vs $-0.41beat
- Fri, Mar 6$-0.34 vs $-0.40beat
- Wed, Nov 12$-0.40 vs $-0.40beat
- Thu, Aug 7$-0.41 vs $-0.39miss
- Fri, May 9$-0.34 vs $-0.37beat
Estimates and results for PMVP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PMVP officers and directors.
- Bought
- —
- Sold
- $2.9m
0 trades
11 trades
- Orbimed Advisors Llcsold
- Orbimed Advisors Llcsold
- Ticktin Robertsold
- Jalota Deepikasold
- Carulli Michaelsold
- Mack David Henrysold
- Jalota Deepikasold
- Carulli Michaelsold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PMVP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.